International Journal of Hematology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma
In this study, we retrospectively analyzed CMV infections in 53 patients with NDMM who received daratumumab as induction therapy. CMV infection was defined as CMV antigenemia positivity. The median age at treatment initiation was 71 years (range, 50-82 years), and 50.9% of the patients were female. The median duration of daratumumab administration was 10.0 months (range, 0.3-63.8 months). Nine patients developed CMV infection, and the cumulative incidence rate at six months was 18.1% (95% confidence interval: 8.9-30.1%). One patient experienced CMV retinitis and required antiviral therapy, while the remaining eight patient...
Source: International Journal of Hematology - April 19, 2024 Category: Hematology Authors: Taku Kikuchi Nobuhiro Tsukada Kodai Kunisada Moe Nomura-Yogo Yuki Oda Kota Sato Tomomi Takei Mizuki Ogura Yu Abe Kenshi Suzuki Tadao Ishida Source Type: research

An unfavorable and a successful pregnancy outcome during and after treatment of gamma heavy chain disease
Int J Hematol. 2024 Apr 18. doi: 10.1007/s12185-024-03769-1. Online ahead of print.ABSTRACTGamma heavy chain disease (gHCD) is a rare B-cell lymphoproliferative disorder that mostly occurs after childbearing age. Here we report the first case of gHCD in a pregnant patient that was diagnosed in the second trimester, and another pregnancy in the same patient after initial treatment for gHCD. The former pregnancy ended in intrauterine fetal death, believed to be caused by insufficient maternal blood flow due to multiple placental infarcts. The latter pregnancy course was uneventful. Although we cannot rule out the possibility...
Source: International Journal of Hematology - April 18, 2024 Category: Hematology Authors: Masataka Hosoi Kazunori Ueno Jun Kikuchi Jun Miyauchi Reina Ooka Kaito Takikawa Yuya Arai Misato Kikuchi Takuro Watanabe Source Type: research

JSH practical guidelines for hematological malignancies, 2023: leukemia-2-acute promyelocytic leukemia (APL)
Int J Hematol. 2024 Apr 17. doi: 10.1007/s12185-024-03749-5. Online ahead of print.NO ABSTRACTPMID:38630356 | DOI:10.1007/s12185-024-03749-5 (Source: International Journal of Hematology)
Source: International Journal of Hematology - April 17, 2024 Category: Hematology Authors: Hiroyuki Fujita Source Type: research

Bernard-Soulier syndrome caused by a novel GP1BB variant and 22q11.2 deletion
Int J Hematol. 2024 Apr 16. doi: 10.1007/s12185-024-03768-2. Online ahead of print.ABSTRACTBernard-Soulier syndrome (BSS) is caused by defects in GP1BA, GP1BB, or GP9 genes. Patients with 22q11.2 deletion syndrome (22q11.2DS) are obligate carriers of BSS because GP1BB resides on chromosome 22q11.2. A 15-month-old girl without bleeding symptoms had giant platelets and thrombocytopenia. Physical findings and macrothrombocytopenia suggested 22q11.2DS, which was confirmed by fluorescence in situ hybridization. Flow cytometry showed decreased GPIbα on the platelets. Gene panel testing revealed a novel variant in GP1BB, p.(Val1...
Source: International Journal of Hematology - April 16, 2024 Category: Hematology Authors: Rintaro Nagoshi Atsushi Sakamoto Tsuyoshi Imai Toru Uchiyama Tadashi Kaname Shinji Kunishima Akira Ishiguro Source Type: research

Spontaneous regression of multiple solitary plasmacytoma harboring Epstein-Barr virus: a case report and literature review
We report a rare case of spontaneous regression (SR) in an elderly untreated patient with multiple solitary plasmacytoma (MSP). Diagnosis of MSP was confirmed through surgical resection of the left nasal cavity mass and subsequent biopsy of the right humerus. The patient was considered ineligible for chemotherapy due to poor performance status. At 3-month post-diagnosis, the patient's condition worsened with deteriorating bone lesions and emergence of a new serum monoclonal protein. However, these clinical findings completely disappeared at 6 months, and positron emission tomography-computed tomography at 1 year confirmed ...
Source: International Journal of Hematology - April 15, 2024 Category: Hematology Authors: Wataru Kitamura Hiroki Kobayashi Minori Noda Akiko Iseki Yumi Sato Yoshinobu Maeda Shoichi Kuyama Source Type: research

Honeycomb lung appearance accompanied by pediatric Langerhans cell histiocytosis: changes in imaging findings following chemotherapy
Int J Hematol. 2024 Apr 15. doi: 10.1007/s12185-024-03776-2. Online ahead of print.NO ABSTRACTPMID:38622431 | DOI:10.1007/s12185-024-03776-2 (Source: International Journal of Hematology)
Source: International Journal of Hematology - April 15, 2024 Category: Hematology Authors: Kenichi Sakamoto Osamu Miyazaki Yoko Shioda Source Type: research

Bispecific antibodies for multiple myeloma: past, present and future
Int J Hematol. 2024 Apr 13. doi: 10.1007/s12185-024-03766-4. Online ahead of print.ABSTRACTDespite the development of various therapeutic agents, multiple myeloma remains incurable. Recently, T-cell redirected immunotherapy has become a promising strategy for the treatment of refractory myeloma. Clinical trials using chimeric antigen receptor (CAR)-T cells and bispecific antibodies have demonstrated successful anti-myeloma responses in triple-class-refractory patients. However, unique and unwanted immune effects associated with on-target/off-target reactivity of activated immune cells need to be considered and properly man...
Source: International Journal of Hematology - April 13, 2024 Category: Hematology Authors: Toshiki Ochi Tatsuya Konishi Katsuto Takenaka Source Type: research

A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom's macroglobulinemia
This study evaluated the efficacy and safety of ibrutinib-rituximab in Japanese patients with WM. Patients received ibrutinib 420 mg orally once daily plus weekly rituximab 375 mg/m2 IV (8 infusions total). The primary end point was major response rate (MRR; PR or better) by Independent Review Committee assessment. Secondary endpoints were progression-free survival (PFS), safety, pharmacokinetics, and biomarkers. Primary analysis was conducted in 16 patients [baseline, treatment naïve: 8 (50.0%); relapsed/refractory WM: 8 (50.0%)] who received ibrutinib-rituximab, after all patients completed Week 57 or end of treatment. ...
Source: International Journal of Hematology - April 10, 2024 Category: Hematology Authors: Koji Izutsu Hisashi Kato Naohiro Sekiguchi Tomoaki Fujisaki Toshiro Kawakita Naoshi Obara Kosei Matsue Mitsutaka Nishimoto Tomoyoshi Hatayama Mitsuo Inagaki Ei Fujikawa Source Type: research

Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group
This study investigated changes in treatment modalities and outcomes of chronic myeloid leukemia in the chronic phase (CP-CML) after the approval of second-generation tyrosine kinase inhibitors (2G-TKIs) for first-line therapy. Patients were grouped into those who underwent TKI therapy up to December 2010 (imatinib era group, n = 185) and after January 2011 (2G-TKI era group, n = 425). All patients in the imatinib era group were initially treated with imatinib, whereas patients in the 2G-TKI era group were mostly treated with dasatinib (55%) or nilotinib (36%). However, outcomes including progression-free survival, overall...
Source: International Journal of Hematology - April 8, 2024 Category: Hematology Authors: Noriyoshi Iriyama Eisaku Iwanaga Yuta Kimura Naoki Watanabe Maho Ishikawa Hitomi Nakayama Eriko Sato Takayuki Tabayashi Toru Mitsumori Tomoiku Takaku Tomonori Nakazato Michihide Tokuhira Hiroyuki Fujita Miki Ando Yoshihiro Hatta Tatsuya Kawaguchi Source Type: research